Clinical Neuropharmacology · 2018 · 56 citations · 10 references
PharmacyPharmacologyPharmacotherapyClinical PharmacologyPain ManagementPharmacovigilanceAdverse Drug Event PreventionHeadache DisordersHeadache ManagementMigraine PharmacotherapyAcute Migraine TreatmentMigraine PharmacologyMigraine ProphylaxisPreventive Headache TherapyPreventive Migraine TherapyPreventive Migraine TreatmentProphylactic Use
OBJECTIVES: To evaluate the prophylactic effects of atorvastatin on frequency, intensity, and duration of migraine attacks compared with sodium valproate. METHODS: In this randomized, double-blind, single-center controlled trial, patients with 6 to 15 migraine attacks per month, which were candidates of preventive treatment, were recruited. The patients were randomly allocated into 2 groups. The first group (A) received atorvastatin 40 mg daily, and the second group (B) received sodium valproate 500 mg daily. All patients were visited each month and followed up for 3 months. The characteristics of migraine headaches including frequency, intensity, and duration of attacks were recorded, as well as the number of analgesics taken per each attack and probable adverse effects. RESULTS: From 100 patients enrolled in the study, 18 cases were excluded owing to adverse effects (2 cases) or lost to follow-up (16 cases). From 82 patients who completed the trial, 46 and 36 were in group A (atorvastatin) and group B (sodium valproate), respectively. Mean age of the patients was not significantly different in the 2 arms of the study (33.56 ± 8.51 in group A and 33.25 ± 9.91 years in group B, P = 0.877). Number, duration, and intensity of attacks and number of analgesics taken during attacks decreased significantly in both groups in monthly follow-ups. However, there was no statistically significant difference between 2 arms of the study in terms of attenuation in the characteristics of migraine attacks. On the other hand, patients in group A suffered fewer adverse effects compared with group B. CONCLUSIONS: This study indicates that atorvastatin could be an alternative for sodium valproate in migraine prophylaxis with comparable efficacy and fewer adverse effects. Multicenter studies with larger sample size are recommended.
10
The International Classification of Headache Disorders, 3rd edition (beta version)
Cephalalgia · 2013 · 8.2K citations · Full text
Medicine, Neurology, Psychiatry +14
Migraine Prophylaxis With Divalproex
N. T. Mathew, Joel R. Saper, Stephen D. Silberstein et al. · Archives of Neurology · 1995 · 327 citations
Divalproex Sodium in Migraine Prophylaxis
J. A. Klapper · Cephalalgia · 1997 · 277 citations